Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Benitec Biopharma (BNTC) Gains from Investment Securities (2019 - 2025)

Benitec Biopharma has reported Gains from Investment Securities over the past 4 years, most recently at $2.0 million for Q4 2025.

Quarterly results put Gains from Investment Securities at $2.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $2.0 million (changed N/A YoY), and the annual figure for FY2025 was $4.9 million, changed.
Gains from Investment Securities reached $2.0 million in Q4 2025 per BNTC's latest filing, down from $4.9 million in the prior quarter.
Across five years, Gains from Investment Securities topped out at $4.9 million in Q2 2025 and bottomed at $794000.0 in Q3 2021.